Drugs / Bivalent influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03564444 | Jun → Dec 2018 | influenza | MedImmune LLC | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03564444 ↗ |
| Modality | Vaccine | “2 new influenza virus vaccine strains” NCT03564444 ↗ |
| Route | Intranasal | “A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered...” NCT03564444 ↗ |